Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 169

1.

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators.

J Am Coll Cardiol. 2019 Aug 27;74(8):1159-1161. doi: 10.1016/j.jacc.2019.06.043. No abstract available.

2.

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.

Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology.

Circulation. 2019 Sep 17;140(12):e673-e691. doi: 10.1161/CIR.0000000000000709. Epub 2019 Aug 19.

PMID:
31422671
3.

Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials.

Ferdinand KC, Jacobson TA, Koren A, Elassal J, Thompson D, Deedwania P.

J Clin Lipidol. 2019 Jul - Aug;13(4):586-593.e5. doi: 10.1016/j.jacl.2019.06.002. Epub 2019 Jun 27.

4.

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE.

J Clin Lipidol. 2019 May - Jun;13(3):374-392. doi: 10.1016/j.jacl.2019.04.010. Epub 2019 May 17.

PMID:
31147269
5.

The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy.

Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, López JAG, Xiang P, Bushnell DM, Martin ML, Cohen JD.

J Clin Lipidol. 2019 May - Jun;13(3):415-424. doi: 10.1016/j.jacl.2019.04.011. Epub 2019 May 18.

PMID:
31113745
6.

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators.

J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.

7.

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council.

Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073. Erratum in: Arterioscler Thromb Vasc Biol. 2019 May;39(5):e158.

PMID:
30580575
8.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators.

N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.

PMID:
30415628
9.

Safety and efficacy of statin therapy.

Adhyaru BB, Jacobson TA.

Nat Rev Cardiol. 2018 Dec;15(12):757-769. doi: 10.1038/s41569-018-0098-5. Review.

PMID:
30375494
10.

Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2018 Jul 14;39(27):2526-2539. doi: 10.1093/eurheartj/ehy182.

11.

Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey.

Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD.

J Clin Lipidol. 2018 Jan - Feb;12(1):78-88. doi: 10.1016/j.jacl.2017.09.006. Epub 2017 Oct 12.

12.

Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins.

Adhyaru BB, Jacobson TA.

Evid Based Med. 2017 Dec;22(6):210. doi: 10.1136/ebmed-2017-110783. Epub 2017 Oct 22. Review. No abstract available.

PMID:
29056606
13.

Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy.

Taylor BA, Sanchez RJ, Jacobson TA, Chibedi-De-Roche D, Manvelian G, Baccara-Dinet MT, Khan I, Rosenson RS.

J Am Coll Cardiol. 2017 Sep 26;70(13):1680-1681. doi: 10.1016/j.jacc.2017.07.767. No abstract available.

14.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association.

Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG.

J Clin Lipidol. 2017 Jul - Aug;11(4):891-900. doi: 10.1016/j.jacl.2017.04.120. Epub 2017 May 24.

15.

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.

Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, Underberg JA.

J Clin Lipidol. 2017 Jul - Aug;11(4):880-890. doi: 10.1016/j.jacl.2017.05.001. Epub 2017 May 19.

16.

Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.

Adhyaru BB, Jacobson TA.

Curr Atheroscler Rep. 2017 Jun;19(6):29. doi: 10.1007/s11883-017-0666-x. Review.

PMID:
28500517
17.

The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.

Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, Taylor B, Khan I, Manvelian G, White M, Jacobson TA.

Cardiovasc Drugs Ther. 2017 Apr;31(2):179-186. doi: 10.1007/s10557-017-6723-4.

18.

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; REDUCE-IT Investigators.

Clin Cardiol. 2017 Mar;40(3):138-148. doi: 10.1002/clc.22692. Epub 2017 Mar 15.

19.

Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.

Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian D; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology.

Circulation. 2017 Apr 11;135(15):e867-e884. doi: 10.1161/CIR.0000000000000482. Epub 2017 Mar 13. Review.

PMID:
28289069
20.

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH.

Patient. 2017 Jun;10(3):321-334. doi: 10.1007/s40271-016-0211-y.

Supplemental Content

Loading ...
Support Center